Related references
Note: Only part of the references are listed.Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma
Thomas E. Hutson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Genome-wide association meta-analysis for total serum bilirubin levels
Andrew D. Johnson et al.
HUMAN MOLECULAR GENETICS (2009)
Survival After Second Primary Neoplasms of the Brain or Spinal Cord in Survivors of Childhood Cancer: Results From the British Childhood Cancer Survivor Study
Aliki J. Taylor et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
Stefan Sleijfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib
Y. Loriot et al.
ANNALS OF ONCOLOGY (2008)
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
Bryan P. Schneider et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2
Qin Ryan et al.
ONCOLOGIST (2008)
THE DELAY FROM THE LAST CYCLE OF DOCETAXEL-BASED CHEMOTHERAPY TO PROGRESSION IS A STRONG PREDICTIVE FACTOR OF ACTIVITY OF SECOND LINE DOCETAXEL IN CASTRATION-RESISTANT PROSTATE CANCER
Y. Loriot et al.
ANNALS OF ONCOLOGY (2008)
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia
J. B. Singer et al.
LEUKEMIA (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Implications of genetic polymorphisms in drug transporters for pharmacotherapy
R Kerb
CANCER LETTERS (2006)
Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles
C Rodríguez-Antona et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Single nucleotide polymorphisms modify the transporter activity of ABCG2
K Morisaki et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2
S Mizuarai et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy
M Wong et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia
TM Danoff et al.
PHARMACOGENOMICS JOURNAL (2004)
Genetic polymorphism of CYP1A2 in ethiopians affecting induction and expression: Characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1
E Aklillu et al.
MOLECULAR PHARMACOLOGY (2003)
Hypoxia-inducible factor-1 alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance
K Tanimoto et al.
CARCINOGENESIS (2003)
Highly parallel SNP genotyping
JB Fan et al.
COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY (2003)
CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes
N Bahadur et al.
BIOCHEMICAL PHARMACOLOGY (2002)
Inducibility of CYP1A2 by orneprazole in vivo related to the genetic polymorphism of CYP1A2
XM Han et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): A nllele frequencies in the Japanese population and functional analysis
T Nozawa et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia
J Sugatani et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
Mechanism of indinavir-induced hyperbilirubinemia
SD Zucker et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid
D Dai et al.
PHARMACOGENETICS (2001)
Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene
MTM Raijmakers et al.
JOURNAL OF HEPATOLOGY (2000)
Share Paper
